Zurgil U, Ben-Ari A, Atias K, Isakov N, Apte R, Livneh E
The Shraga Segal Department of Microbiology Immunology and Genetics, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
Cell Death Dis. 2014 Nov 20;5(11):e1531. doi: 10.1038/cddis.2014.481.
Senescence is characterized by permanent cell-cycle arrest despite continued viability and metabolic activity, in conjunction with the secretion of a complex mixture of extracellular proteins and soluble factors known as the senescence-associated secretory phenotype (SASP). Cellular senescence has been shown to prevent the proliferation of potentially tumorigenic cells, and is thus generally considered a tumor suppressive process. However, some SASP components may act as pro-tumorigenic mediators on premalignant cells in the microenvironment. A limited number of studies indicated that protein kinase C (PKC) has a role in senescence, with different isoforms having opposing effects. It is therefore important to elucidate the functional role of specific PKCs in senescence. Here we show that PKCη, an epithelial specific and anti-apoptotic kinase, promotes senescence induced by oxidative stress and DNA damage. We further demonstrate that PKCη promotes senescence through its ability to upregulate the expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1) and enhance transcription and secretion of interleukin-6 (IL-6). Moreover, we demonstrate that PKCη creates a positive loop for reinforcing senescence by increasing the transcription of both IL-6 and IL-6 receptor, whereas the expression of IL-8 is specifically suppressed by PKCη. Thus, the presence/absence of PKCη modulates major components of SASP. Furthermore, we show that the human polymorphic variant of PKCη, 374I, that exhibits higher kinase activity in comparison to WT-374V, is also more effective in IL-6 secretion, p21(Cip1) expression and the promotion of senescence, further supporting a role for PKCη in senescence. As there is now considerable interest in senescence activation/elimination to control tumor progression, it is first crucial to reveal the molecular regulators of senescence. This will improve our ability to develop new strategies to harness senescence as a potential cancer therapy in the future.
衰老的特征是尽管细胞仍具有活力和代谢活性,但细胞周期却永久停滞,同时还会分泌一种复杂的细胞外蛋白质和可溶性因子混合物,即衰老相关分泌表型(SASP)。细胞衰老已被证明可阻止潜在致瘤细胞的增殖,因此通常被认为是一种肿瘤抑制过程。然而,一些SASP成分可能作为微环境中癌前细胞的促瘤介质。有限的研究表明,蛋白激酶C(PKC)在衰老过程中发挥作用,不同的同工型具有相反的作用。因此,阐明特定PKC在衰老中的功能作用非常重要。在这里,我们表明PKCη是一种上皮特异性抗凋亡激酶,可促进氧化应激和DNA损伤诱导的衰老。我们进一步证明,PKCη通过上调细胞周期抑制剂p21(Cip1)和p27(Kip1)的表达以及增强白细胞介素-6(IL-6)的转录和分泌来促进衰老。此外,我们证明PKCη通过增加IL-6和IL-6受体的转录来形成一个增强衰老的正反馈环,而IL-8的表达则被PKCη特异性抑制。因此,PKCη的存在与否调节了SASP的主要成分。此外,我们表明,与WT-374V相比,表现出更高激酶活性的PKCη人类多态变体374I在IL-6分泌、p21(Cip1)表达和衰老促进方面也更有效,进一步支持了PKCη在衰老中的作用。由于目前人们对激活/消除衰老以控制肿瘤进展有相当大的兴趣,首先至关重要的是揭示衰老的分子调节因子。这将提高我们未来开发新策略以利用衰老作为潜在癌症治疗方法的能力。